Resolution of lymphoma-associated open-angle glaucoma by rituximab

Won I. Kim, Jeanette G. Larar, Bruce D. Cheson, Richard K. Lee, Paul F. Palmberg

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Purpose: To report a patient who developed open-angle glaucoma, secondary to bilateral perilimbal conjunctival lymphoid infiltrates without intraocular involvement that resolved after treatment with systemic rituximab. Methods: Observational case report. Results: Review of historic, clinical, and photographic data of a 67-year-old woman with non-Hodgkin lymphoma of the axillary and cervical lymph nodes and bilateral perilimbal conjunctival lymphoid infiltrates who presented for treatment of uncontrolled chronic open-angle glaucoma on maximum medical therapy. The elevated intraocular pressures and conjunctival lesions resolved after treatment of the systemic lymphoma with rituximab. The patient was followed for a period of 6 years without recurrence of the conjunctival lesions, with low normal intraocular pressures without progressive optic nerve damage off all glaucoma treatments. Conclusions: Open-angle glaucoma can result as a consequence of isolated conjunctival lymphoid tumors and can resolve with successful treatment of lymphoid lesions. The mechanism of glaucoma may be obstruction of aqueous outflow to the episcleral and conjunctival veins either by compression from a mass effect or direct infiltration that is relieved with resolution of the conjunctival lymphoid lesions. We believe this is a unique presentation of glaucoma associated with lymphoid tumors that has not been reported earlier.

Original languageEnglish (US)
Pages (from-to)398-400
Number of pages3
JournalJournal of glaucoma
Issue number6
StatePublished - Aug 1 2011


  • conjunctival lymphoma
  • glaucoma
  • lymphoma
  • ocular adnexal lymphoma
  • open-angle glaucoma
  • rituximab

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Resolution of lymphoma-associated open-angle glaucoma by rituximab'. Together they form a unique fingerprint.

Cite this